Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Ambisome (liposomal amphotericin B)

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section
Selected DailyMed label (opens in a new tab)

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

Ambisome (amphotericin B) (opens in a new tab)Original source URL: https://globalrph.com/dilution/ambisome-ampho-b/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/ambisome-ampho-b/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:45:48.924093+00:00
Source location
div.post-content
Packaged content SHA-256
91f4150c83d2550e1d4d9daf1cdc937622f7f335e32f3d817ad77ac79a5ab571
Original response SHA-256
831d2f3097606b706d5b47fb8ef0aaf9b536ef7389548ed56ec4c1294d820efa
Source body SHA-256
88a5faaa97a2f2bac661008140f1a18eec126ecefe8954b93a3f22fe2dc86db1

Amphotericin B (Liposomal) - Ambisome

Usual Diluents
D5W

Standard Dilution [Amount of drug] [Infusion volume] [Infusion rate]
[3 - 6 mg/kg/day] [Final concentration: 1-2 mg/ml] [120 minutes*]

*Infusion time may be reduced to approximately 60 minutes in patients in whom the treatment is well-tolerated. If the patient experiences discomfort during infusion, the duration of infusion may be increased. Final concentrations of 0.2 - 0.5 mg/ml may be appropriate for infants and small children to provide sufficient volume for infusion.

Vial Reconstitution:
1. Aseptically add 12 mL of Sterile Water for Injection, USP to each AmBisome vial to yield a preparation containing 4 mg amphotericin B/mL.

CAUTION: DO NOT RECONSTITUTE WITH SALINE OR ADD SALINE TO THE RECONSTITUTED CONCENTRATION, OR MIX WITH OTHER DRUGS. The use of any solution other than those recommended, or the presence of a bacteriostatic agent in the solution, may cause precipitation of AmBisome.

2. Immediately after the addition of water, SHAKE THE VIAL VIGOROUSLY for 30 seconds to completely disperse the AmBisome. AmBisome forms a yellow, translucent suspension. Visually inspect the vial for particulate matter and continue shaking until completely dispersed.

Filtration and Dilution
3. Calculate the amount of reconstituted (4 mg/mL) AmBisome to be further diluted.

4. Withdraw this amount of reconstituted AmBisome into a sterile syringe.

5. Attach the 5-micron filter, provided, to the syringe. Inject the syringe contents through the filter, into the appropriate amount of 5% Dextrose Injection. (Use only one filter per vial of AmBisome.)

6. AmBisome must be diluted with 5% Dextrose Injection to a final concentration of 1 to 2 mg/mL prior to administration. Lower concentrations (0.2 to 0.5 mg/mL) may be appropriate for infants and small children to provide sufficient volume for infusion. DISCARD PARTIALLY USED VIALS.

Stability / Miscellaneous
Stability (see below).

Stability data:
Drug Stability
Refrigerated		 Stability
Room Temp.		 Reconstituted
Vial/Powder		 Notes
Ambisome (Ampho B) The reconstituted product concentrate may be stored for up to 24 hours at 2º-8º C (36º-46º F) following reconstitution with Sterile Water for Injection, USP. Unopened vials of lyophilized material are to be stored at temperatures up to 25° C (77° F) Powder Discard partially used vials.
Do not freeze.

MICROBIOLOGY
Mechanism of Action
Amphotericin B, the active ingredient of AmBisome, acts by binding to the sterol component of a cell membrane leading to alterations in cell permeability and cell death. While amphotericin B has a higher affinity for the ergosterol component of the fungal cell membrane, it can also bind to the cholesterol component of the mammalian cell leading to cytotoxicity. AmBisome, the liposomal preparation of amphotericin B, has been shown to penetrate the cell wall of both extracellular and intracellular forms of susceptible fungi.

Activity In Vitro and In Vivo
AmBisome has shown in vitro activity comparable to amphotericin B against the following organisms: Aspergillus species (A. fumigatus, A. flavus), Candida species (C. albicans, C. krusei, C. lusitaniae, C. parapsilosis, C. tropicalis), Cryptococcus neoformans, and Blastomyces dermatitidis. However, standardized techniques for susceptibility testing of antifungal agents have not been established and results of such studies do not necessarily correlate with clinical outcome.

AmBisome is active in animal models against Aspergillus fumigatus , Candida albicans, Candida krusei, Candida lusitaniae, Cryptococcus neoformans, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, Paracoccidioides brasiliensis, Leishmania donovani, and Leishmania infantum. The administration of AmBisome in these animal models demonstrated prolonged survival of infected animals, reduction of microorganisms from target organs, or a decrease in lung weight.

Clinical Pharmacology
Pharmacokinetics
The assay used to measure amphotericin B in the serum after administration of AmBisome does not distinguish amphotericin B that is complexed with the phospholipids of AmBisome from amphotericin B that is uncomplexed. The pharmacokinetic profile of amphotericin B after administration of AmBisome is based upon total serum concentrations of amphotericin B. The pharmacokinetic profile of amphotericin B was determined in febrile neutropenic cancer and bone marrow transplant patients who received 1-2 hour infusions of 1 to 5 mg/kg/day AmBisome for 3 to 20 days.

Distribution
Based on total amphotericin B concentrations measured within a dosing interval (24 hours) after administration of AmBisome, the mean half-life was 7-10 hours. However, based on total amphotericin B concentration measured up to 49 days after dosing of AmBisome, the mean half-life was 100-153 hours. The long terminal elimination half-life is probably a slow redistribution from tissues. Steady state concentrations were generally achieved within 4 days of dosing.

Although variable, mean trough concentrations of amphotericin B remained relatively constant with repeated administration of the same dose over the range of 1 to 5 mg/kg/day, indicating no significant drug accumulation in the serum.

Metabolism
The metabolic pathways of amphotericin B after administration of AmBisome are not known.

Excretion
The mean clearance at steady state was independent of dose. The excretion of amphotericin B after administration of AmBisome has not been studied.

INDICATIONS AND USAGE
AmBisome is indicated for the following:
-Empirical therapy for presumed fungal infection in febrile, neutropenic patients.
-Treatment of Cryptococcal Meningitis in HIV infected patients.
-Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate.
-Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with AmBisome, relapse rates were high following initial clearance of parasites.

CONTRAINDICATIONS
AmBisome is contraindicated in those patients who have demonstrated or have known hypersensitivity to amphotericin B deoxycholate or any other constituents of the product unless, in the opinion of the treating physician, the benefit of therapy outweighs the risk. WARNINGS
Anaphylaxis has been reported with amphotericin B deoxycholate and other amphotericin B-containing drugs, including AmBisome. If a severe anaphylactic reaction occurs, the infusion should be immediately discontinued and the patient should not receive further infusions of AmBisome.

DOSAGE AND ADMINISTRATION
AmBisome should be administered by intravenous infusion, using a controlled infusion device, over a period of approximately 120 minutes.

An in-line membrane filter may be used for the intravenous infusion of AmBisome; provided THE MEAN PORE DIAMETER OF THE FILTER IS NOT LESS THAN 1.0 MICRON.

NOTE: An existing intravenous line must be flushed with 5% Dextrose Injection prior to infusion of AmBisome. If this is not feasible, AmBisome must be administered through a separate line.

Infusion time may be reduced to approximately 60 minutes in patients in whom the treatment is well-tolerated. If the patient experiences discomfort during infusion, the duration of infusion may be increased.

The recommended initial dose of AmBisome for each indication for adult and pediatric patients is as follows:

Indication Dose (mg/kg/day)
Empirical therapy 3
Systemic fungal infections:
Aspergillus
Candida
Cryptococcus		 3-5
Cryptococcal meningitis in HIV infected patients (see package insert for DESCRIPTION OF CLINICAL STUDIES) 6

Dosing and rate of infusion should be individualized to the needs of the specific patient to ensure maximum efficacy while minimizing systemic toxicities or adverse events.

Doses recommended for visceral leishmaniasis are presented below:

Visceral Leishmaniasis Dose (mg/kg/day)
Immunocompetent patients 3 (days 1-5) and 3 on days 14, 21
Immunocompromised patients 4 (days 1-5) and 4 on days 10, 17, 24, 31, 38

For immunocompetent patients who do not achieve parasitic clearance with the recommended dose, a repeat course of therapy may be useful.

For immunocompromised patients who do not clear parasites or who experience relapses, expert advice regarding further treatment is recommended. For additional information see package insert for DESCRIPTION OF CLINICAL STUDIES.

Directions for Reconstitution, Filtration and Dilution
Read This Entire Section Carefully Before Beginning Reconstitution

AmBisome must be reconstituted using Sterile Water for Injection, USP (without a bacteriostatic agent). Vials of AmBisome containing 50 mg of amphotericin B are prepared as follows:

Reconstitution
1. Aseptically add 12 mL of Sterile Water for Injection, USP to each AmBisome vial to yield a preparation containing 4 mg amphotericin B/mL.

CAUTION: DO NOT RECONSTITUTE WITH SALINE OR ADD SALINE TO THE RECONSTITUTED CONCENTRATION, OR MIX WITH OTHER DRUGS. The use of any solution other than those recommended, or the presence of a bacteriostatic agent in the solution, may cause precipitation of AmBisome.

2. Immediately after the addition of water, SHAKE THE VIAL VIGOROUSLY for 30 seconds to completely disperse the AmBisome. AmBisome forms a yellow, translucent suspension. Visually inspect the vial for particulate matter and continue shaking until completely dispersed.

Filtration and Dilution
3. Calculate the amount of reconstituted (4 mg/mL) AmBisome to be further diluted.

4. Withdraw this amount of reconstituted AmBisome into a sterile syringe.

5. Attach the 5-micron filter, provided, to the syringe. Inject the syringe contents through the filter, into the appropriate amount of 5% Dextrose Injection. (Use only one filter per vial of AmBisome.)

6. AmBisome must be diluted with 5% Dextrose Injection to a final concentration of 1 to 2 mg/mL prior to administration. Lower concentrations (0.2 to 0.5 mg/mL) may be appropriate for infants and small children to provide sufficient volume for infusion. DISCARD PARTIALLY USED VIALS.

STORAGE OF AMBISOME
Unopened vials of lyophilized material are to be stored at temperatures up to 25° C (77° F).

Storage of Reconstituted Product Concentrate
The reconstituted product concentrate may be stored for up to 24 hours at 2º-8º C (36º-46º F) following reconstitution with Sterile Water for Injection, USP. Do not freeze.

Storage of Diluted Product
Injection of AmBisome should commence within 6 hours of dilution with 5% Dextrose Injection.

As with all parenteral drug products, the reconstituted AmBisome should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use material if there is any evidence of precipitation or foreign matter. Aseptic technique must be strictly observed in all handling since no preservative or bacteriostatic agent is present in AmBisome or in the materials specified for reconstitution and dilution.

HOW SUPPLIED
AmBisome for Injection is available as single vial cartons (equivalent to 50mg amphotericin B) and in packs of ten individual vial cartons

(NDC 0469-3051-30).
Each carton contains one pre-packaged, disposable sterile 5 micron filter.
Rx only

Marketed by:
Astellas Pharma US, Inc.
Deerfield, IL 60015-2548

Manufactured by:
Gilead Sciences, Inc.
San Dimas, CA 91773
AmBisome is a registered trademark of Gilead Sciences, Inc.
Abelcet® is a registered trademark of The Liposome Company, Inc.
10062008AMB
Revised: 10/2008 Astellas Pharma US, Inc.

Reference(s)
Package Insert: Astellas Pharma US, Inc. Deerfield, IL 60015-2548. Revised: 10/2008

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • A retrieved source document is available; clinical reconciliation and a second-source claim map remain incomplete
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
monitor_or_titrate
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      • Source kind
        label_snapshot
        Local pointer
        /mechanism_summary
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        GlobalRPh drug-specific mechanism summary retained alongside the selected DailyMed label.
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      ambisome-liposomal-amphotericin-b
      Source IDH51-83300AA57A64233B45BD70A5
      Generic name
      Ambisome (liposomal amphotericin B)
      Source IDH51-34ECBED910BAE5AC00C7E80D
      Class
      Antifungal
      Source IDH51-C039C7A277A854CCBCC2EFC1
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-4DE2AB6F698786B4718899CE
      Primary uses
      1. Severe or invasive fungal infection when the organism, site, patient factors, and current labeling support IV therapy.
        Source IDH51-F7F1DFE769500BDB339262E4
      Mechanism
      Binds fungal membrane ergosterol, forms pores, and causes leakage of intracellular contents.
      Source IDH51-42F7147AF4A697C674EA0A24
      Mechanism level
      drug_specific
      Source IDH51-3A7E30D1E1FA91AC41709FCB
      Basic dosing orientation
      Adult dosing is indication- and patient-specific. Pediatric use is label supported for selected indications; concentration and fluid volume require weight-appropriate review. Do not infer neonatal dosing from adult tables; use neonatal infectious-disease guidance and the current label.
      Source IDH51-65C0079D43A62B31B9945AE7
      Administration orientation
      Usually infuse over approximately 120 minutes; the current label describes circumstances in which a shorter infusion may be used in a tolerant patient. Use the supplied 5-micron filter to transfer reconstituted drug into D5W. An in-line membrane filter may be used during infusion only when its mean pore diameter is at least 1 micron. Flush an existing line with D5W or use a separate line.
      Source IDH51-44963218DC43B59592DEA111
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal function materially affects toxicity, monitoring, or titration even when a fixed table may not apply.
      Source IDH51-D7A5A34B5CC396DE54768D66
      Key safety orientation
      1. AmBisome is not interchangeable on a mg-per-mg basis with other amphotericin B products. Use D5W, not saline, for final dilution.
        Source IDH51-9321FC0EEF8D8DC9844A540D
      2. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-5F4C4E5D1020BFD566A0D130
      Coverage path
      reviewed_local_label_summary
      Source IDH51-8E09C87731A96326185F8A49
      Coverage path label
      Reviewed local package-insert summary
      Source IDH51-4C4123A66678B73B5BDB52CF
      Legacy title
      Ambisome (liposomal amphotericin B)
      Source IDH51-BD36CE9EBED6A449FF1F8AB3
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-E3B0A85D97BABC1F8FC3F961
      Search text
      Ambisome (liposomal amphotericin B) Antifungal Legacy GlobalRPh directory entry Severe or invasive fungal infection when the organism, site, patient factors, and current labeling support IV therapy. Binds fungal membrane ergosterol, forms pores, and causes leakage of intracellular contents. Adult dosing is indication- and patient-specific. Pediatric use is label supported for selected indications; concentration and fluid volume require weight-appropriate review. Do not infer neonatal dosing from adult tables; use neonatal infectious-disease guidance and the current label. Usually infuse over approximately 120 minutes; the current label describes circumstances in which a shorter infusion may be used in a tolerant patient. Use the supplied 5-micron filter to transfer reconstituted drug into D5W. An in-line membrane filter may be used during infusion only when its mean pore diameter is at least 1 micron. Flush an existing line with D5W or use a separate line. Renal function materially affects toxicity, monitoring, or titration even when a fixed table may not apply. AmBisome is not interchangeable on a mg-per-mg basis with other amphotericin B products. Use D5W, not saline, for final dilution. Legacy content must be reconciled against current labeling and institutional policy before clinical use. Reviewed local package-insert summary
      Source IDH51-463F8355A3EF11CDED6BA541
      Official access mode
      direct_label
      Source IDH51-4C67208887D2E7B3E28A84A7
      Official access reason
      A source-specific DailyMed label route is available.
      Source IDH51-57D78EFEFF33A0E51E322A19
      Label snapshot available
      true
      Source IDH51-6D5EB9950BEF5CA698060862
      Label snapshot setid
      f7be6506-4d20-401e-a0ff-02ad7c33158a
      Source IDH51-CA1D3751BAEB6F884863D295

      No separate structured rows were bundled for preparation, IV push, continuous infusion, population dosing, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical local label preparation summary

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      ambisome
      Source IDH51-4F93DE66CB2CA91E91E3D9CE
      Match names
      1. Ambisome
        Source IDH51-C12E4FA13C50E69569BC217D
      2. Liposomal amphotericin B
        Source IDH51-47DED0C5B8771182C0CCFEFE
      3. Amphotericin B liposomal
        Source IDH51-1CC04D679E0CA53F7B08C696
      Label title
      Amphotericin B liposome for injection (AmBisome)
      Source IDH51-3A208A49171ADBF4D76E4239
      Brand names
      1. AmBisome
        Source IDH51-668005E89BFDFFA98AFD2B24
      Formulation
      50 mg liposomal amphotericin B lyophilized vial.
      Source IDH51-74A011348366CF8A15371602
      Reconstitution
      Reconstitute each 50 mg vial with 12 mL Sterile Water for Injection to produce 4 mg/mL. Do not reconstitute with saline or add a bacteriostatic agent.
      Source IDH51-1C5848AC70FCC1224EE84133
      Stock concentration
      4 mg/mL after labeled reconstitution.
      Source IDH51-E868FB133B554AFFCC0BA08A
      Diluents
      Further dilute only with 5% dextrose injection unless the exact current label states otherwise.
      Source IDH51-668A45BA8A5088E22F669451
      Final concentration
      Common labeled final concentrations are 1 to 2 mg/mL; lower concentrations may be required for infants and small children.
      Source IDH51-4159E4F0455792518A142F09
      Containers
      Select a D5W container that produces the labeled final concentration and accommodates the total dose volume.
      Source IDH51-DF0E9D91E128D06349DA903A
      Infusion time
      Usually infuse over approximately 120 minutes; the current label describes circumstances in which a shorter infusion may be used in a tolerant patient.
      Source IDH51-63CAD45445BB982C226A9B6B
      Fluid restriction
      Do not exceed the labeled maximum concentration. Any concentrated preparation requires exact-product and institutional verification.
      Source IDH51-DDD89C0663E4F121F78DE837
      Stability
      The reconstituted 4 mg/mL concentrate may be stored for up to 24 hours at 2 to 8 C. After dilution in D5W, begin the infusion within 6 hours. Do not freeze.
      Source IDH51-5D51D4FD7EB070556F36CD80
      Line filter
      Use the supplied 5-micron filter to transfer reconstituted drug into D5W. An in-line membrane filter may be used during infusion only when its mean pore diameter is at least 1 micron. Flush an existing line with D5W or use a separate line.
      Source IDH51-E4C564C7B598BA2ED93C0947
      Adult applicability
      Adult dosing is indication- and patient-specific.
      Source IDH51-C404AF8DCAEBCE4EAD918BC1
      Pediatric applicability
      Pediatric use is label supported for selected indications; concentration and fluid volume require weight-appropriate review.
      Source IDH51-6FC49F23901A9D01435C947E
      Neonatal applicability
      Do not infer neonatal dosing from adult tables; use neonatal infectious-disease guidance and the current label.
      Source IDH51-1747A2F8CCC20316539FC7BA
      Renal dialysis
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)No routine dose table substitutes for close renal, electrolyte, hepatic, and hematologic monitoring.
      Source IDH51-923D9E64D7B3E5404D8FA614
      Key warnings
      AmBisome is not interchangeable on a mg-per-mg basis with other amphotericin B products. Use D5W, not saline, for final dilution.
      Source IDH51-350D54DCDC9CD04FBBC5C923
      Catalog id
      ambisome-liposomal-amphotericin-b
      Source IDH51-9EC1CA100738F92CCBB930F4
      Catalog name
      Ambisome (liposomal amphotericin B)
      Source IDH51-A3AE0D7C71A88F72A16B5D0D
      Review date
      2026-08-30
      Source IDH51-E5458F60390C7966CE0E78B6
      Source type
      Reviewed local summary derived from official DailyMed labeling; exact marketed product must be checked.
      Source IDH51-DD06B139F8E60CF971ADD79E
      Official link type
      DailyMed official label
      Source IDH51-B1DE79BC33E0299B8A8BF096
      Search text
      Ambisome Liposomal amphotericin B Amphotericin B liposomal AmBisome ambisome ambisome-liposomal-amphotericin-b Ambisome (liposomal amphotericin B) Amphotericin B liposome for injection (AmBisome) 50 mg liposomal amphotericin B lyophilized vial. Reconstitute each 50 mg vial with 12 mL Sterile Water for Injection to produce 4 mg/mL. Do not reconstitute with saline or add a bacteriostatic agent. 4 mg/mL after labeled reconstitution. Further dilute only with 5% dextrose injection unless the exact current label states otherwise. Common labeled final concentrations are 1 to 2 mg/mL; lower concentrations may be required for infants and small children. Select a D5W container that produces the labeled final concentration and accommodates the total dose volume. Usually infuse over approximately 120 minutes; the current label describes circumstances in which a shorter infusion may be used in a tolerant patient. Do not exceed the labeled maximum concentration. Any concentrated preparation requires exact-product and institutional verification. The reconstituted 4 mg/mL concentrate may be stored for up to 24 hours at 2 to 8 C. After dilution in D5W, begin the infusion within 6 hours. Do not freeze. Use the supplied 5-micron filter to transfer reconstituted drug into D5W. An in-line membrane filter may be used during infusion only when its mean pore diameter is at least 1 micron. Flush an existing line with D5W or use a separate line. Adult dosing is indication- and patient-specific. Pediatric use is label supported for selected indications; concentration and fluid volume require weight-appropriate review. Do not infer neonatal dosing from adult tables; use neonatal infectious-disease guidance and the current label. No routine dose table substitutes for close renal, electrolyte, hepatic, and hematologic monitoring. AmBisome is not interchangeable on a mg-per-mg basis with other amphotericin B products. Use D5W, not saline, for final dilution. Current DailyMed label page located during the 2026-08-30 review; confirm the exact NDC and marketed product at the point of use. Reviewed local summary derived from official DailyMed labeling; exact marketed product must be checked. DailyMed official label 2026-08-30
      Source IDH51-2C996FC70F7AFA981782DD1D
      Label status
      Current DailyMed label page located during the 2026-08-30 review; confirm the exact NDC and marketed product at the point of use.
      Source IDH51-58346D01D0E3853E51DD66F8
      Label status level
      current
      Source IDH51-04F0128E8097FBDBAAEDA43B

      Historical DailyMed label snapshot

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      ambisome-liposomal-amphotericin-b
      Source IDH51-BE6AC216367D4CB4C5482362
      Catalog name
      Ambisome (liposomal amphotericin B)
      Source IDH51-FAA8128B89D4358A4953EBD4
      Selection status
      accepted_high_confidence
      Source IDH51-2CA78D8672B3E87CAEFD34FE
      Confidence
      very_high
      Source IDH51-A82CE309F04AF042DCECC4C1
      Match path
      existing_reviewed_summary
      Source IDH51-BE01EB6107A756C9A78CBD76
      Brand name
      AmBisome
      Source IDH51-FCEC1E6FC54F9B7AB90FF7A9
      Label title
      Amphotericin B liposome for injection (AmBisome)
      Source IDH51-1512779A0B19D095C95E3414
      Setid
      f7be6506-4d20-401e-a0ff-02ad7c33158a
      Source IDH51-7944DAD3233378DB29E8FE50
      Reviewed on
      2026-08-31
      Source IDH51-F0ED16EDCBA025D6E5942C51
      Route
      Intravenous; see the selected product label for exact route and administration method.
      Source IDH51-69197839DCD5D70B09B1C7F0
      Dosage form
      50 mg liposomal amphotericin B lyophilized vial.
      Source IDH51-BC26C1380018636784DA5615
      Dosage administration summary
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      1. Adult dosing is indication- and patient-specific.
        Source IDH51-B632DB20DF029BCBFD623E93
      2. Pediatric use is label supported for selected indications; concentration and fluid volume require weight-appropriate review.
        Source IDH51-ECDEBAC7B3CBEC4E0EA0258C
      3. Do not infer neonatal dosing from adult tables; use neonatal infectious-disease guidance and the current label.
        Source IDH51-3B1043FA26B699014DF619CE
      4. Reconstitute each 50 mg vial with 12 mL Sterile Water for Injection to produce 4 mg/mL. Do not reconstitute with saline or add a bacteriostatic agent.
        Source IDH51-744CA13C4D139FC0436F95F0
      5. Usually infuse over approximately 120 minutes; the current label describes circumstances in which a shorter infusion may be used in a tolerant patient.
        Source IDH51-A8B8340ADBECE5E97412DC38
      6. No routine dose table substitutes for close renal, electrolyte, hepatic, and hematologic monitoring.
        Source IDH51-CD508AA8388AE1E84547EEF8
      Dosage forms strengths
      1. 50 mg liposomal amphotericin B lyophilized vial.
        Source IDH51-570F48FA88EEF053C74768FF
      2. 4 mg/mL after labeled reconstitution.
        Source IDH51-08C2A614ED7C192C9B61DB2A
      Mechanism summary
      Binds fungal membrane ergosterol, forms pores, and causes leakage of intracellular contents.
      Source IDH51-D590013D5FEAD957B3F7CD57
      Mechanism source
      GlobalRPh drug-specific mechanism summary retained alongside the selected DailyMed label.
      Source IDH51-A6671D9EB461E01009592A09
      Scope note
      The locally reviewed preparation summary remains the primary product-specific preparation snapshot. This broader label snapshot is concise and does not reproduce the full prescribing information.
      Source IDH51-7B1D97856BDFC423830236FF
      Source sections
      1. Dosage and Administration
        Source IDH51-B7AB4BE7AB0D106267029ACA
      2. Dosage Forms and Strengths
        Source IDH51-7F726265DF87E066D27FD7F0
      3. Clinical Pharmacology or Microbiology as applicable
        Source IDH51-4263441EF035B58ACE17731B
      Retrieval method
      Manual build-time review of the current DailyMed full prescribing information for the selected Set ID; no live server retrieval is required during page use.
      Source IDH51-44F23C88A2F2D61EDC0843B2
      Label status
      current
      Source IDH51-25608FE3F005602E957189E0
      Disclaimer
      Verify the exact formulation, strength, manufacturer, NDC, route, current label revision, patient-specific order, institutional policy, and monitoring before use.
      Source IDH51-9C7473BD575C67484796B130

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      monitor_or_titrate
      Source IDH51-20AC4E52BF1A786F7E748AEF
      Summary
      Renal function materially affects toxicity, monitoring, or titration even when a fixed table may not apply.
      Source IDH51-A2AFC8E015718F516F2EF377
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-31AFA6F8BB2276B675806B0E

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-8A5193B535CCDEC9199BC142

      Historical Stability notes

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy product stability information is not automatically equivalent to a USP <797> BUD.
        Source IDH51-16961C24CEBFE204BE3525A3

      Historical supplemental professional sources

      Recovered v5.1 source content; historical, awaiting current review.

      LabelUrlKind
      Source IDH51-A6E12075903CDD5891491177
      UCSF adult antimicrobial dosing, non-dialysis
      Source IDH51-E3F85CC4D816910EBF367826
      		https://idmp.ucsf.edu/adult-antimicrobial-dosing-non-dialysis (opens in a new tab)
      Source IDH51-45D6CFF74CC06B936D2E5EE0
      		Professional institutional guidance
      Source IDH51-D18B84513D42952B9E23F276
      Source IDH51-8D4BAD3B704EB3A55B7DCEE6
      UCSF antimicrobial dosing in intermittent and continuous hemodialysis
      Source IDH51-DB5EEEC16FFE6D3E4B7A1B72
      		https://idmp.ucsf.edu/antimicrobial-dosing-intermittent-continuous-hemodialysis (opens in a new tab)
      Source IDH51-19ECB5009D4D1B95C742F7F0
      		Professional institutional guidance
      Source IDH51-737244BE32AC3EF6F6272ABF
      Source IDH51-966DC71EC4026E35524E09E2
      UCSF pediatric antimicrobial dosing
      Source IDH51-AB7B696C98D1EB497C275982
      		https://idmp.ucsf.edu/pediatric-antimicrobial-dosing-benioff-childrens-hospitals (opens in a new tab)
      Source IDH51-8C3B2C64261D047B63B41882
      		Professional institutional guidance
      Source IDH51-5D9D3C8B1B8821FB8CF2C5BC
      Source IDH51-F671D436A602C2FAF86417C2
      UCSF neonatal antimicrobial dosing
      Source IDH51-1BDD38A4EABC3E2DF6714631
      		https://idmp.ucsf.edu/neonatal-antimicrobial-dosing-benioff-childrens-hospitals (opens in a new tab)
      Source IDH51-B7E39F9312128BF1D5834F44
      		Professional institutional guidance
      Source IDH51-E386E5A958B2DF4108F8297B
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      ambisome-liposomal-amphotericin-b
      Source IDH51-EE22EE97830911ADD25A4EFD
      Legacy title
      Ambisome (liposomal amphotericin B)
      Source IDH51-ED0D8C3426D779DA2F3C2EEC
      Generic name
      Ambisome (liposomal amphotericin B)
      Source IDH51-D9117625DE231D1DC821900F
      Class
      Antifungal
      Source IDH51-F68C74B4AFA44527B64C0DAB
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-00DDE1BCC3EA3EB2B9253433
      Summary
      Existing GlobalRPh IV dilution monograph retained for migration into the unified reference.
      Source IDH51-57A6F7A8F856B02CF28260D8
      Populations
      1. Population not yet normalized
        Source IDH51-2FC5004EC7ACC0E1BA831DAC
      Evidence tier
      Reviewed local label summary - exact product confirmation required
      Source IDH51-342A34C8EDB74F98AF7B26BF
      High alert
      false
      Source IDH51-05AEA2A4E81644CF7AF5BFCA
      Hazardous
      false
      Source IDH51-344BEEE94362FCBA35EB1676
      Status
      Legacy migration
      Source IDH51-186F32C63B482092DE78A46E
      Reviewed
      2026-08-30
      Source IDH51-A4565211F201D3B3D8EE7461
      Version added
      Legacy
      Source IDH51-8982F134A103365C13696D3B
      Sources
      LabelUrlKind
      Source IDH51-282001229BA41D2A382DC95B
      GlobalRPh legacy IV dilution monograph
      Source IDH51-7F03E718CE886656E56E2377
      		legacy:auto
      Source IDH51-1C075F904868FFD3CA1E9105
      		Legacy
      Source IDH51-5082A15E628B1394953F6767
      Clinical release verification
      Audit version
      3.4
      Source IDH51-F593033C0C6A5FFDE75A7D32
      Audited on
      2026-08-30
      Source IDH51-7446623E0737D6AD09A9D038
      Level
      amber
      Source IDH51-C2F3F2F89656779C491ABF9B
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-8C8B1311851308C31C2ACFE6
      Exact current label candidate
      false
      Source IDH51-C7F045C2620858E5131584B5
      Reference url count
      4
      Source IDH51-45EB51BCC8A6ECCECBB8E8E6
      Broken reference count
      0
      Source IDH51-2C4D35A7230C555C6D85A4C0
      Point of use confirmation required
      true
      Source IDH51-CC28B6C7C300276601A768D5
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-243B131340D4ED8B2497B37C
      Version updated
      3.8
      Source IDH51-08227AB5EF798D8F83824BD4

      Dosing source fields

      Id
      ambisome-liposomal-amphotericin-b
      Source IDH51-CCD004BFDF132299EBA0DDD4
      Generic name
      Ambisome (liposomal amphotericin B)
      Source IDH51-53CD31D35B9564F71F1AA19E
      Coverage status
      direct_official_label_access_plus_legacy_reference
      Source IDH51-8276D0CEA146FE7DD24D31E0
      Package insert
      Query name
      Ambisome
      Source IDH51-5C61E27645014EF498999B54
      Product and route must match
      true
      Source IDH51-6DC6F411CD4F107C1A46EDDA
      Live current label enabled
      false
      Source IDH51-12DB8433F46C02D9B89F0620
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-87815D73001543C0F422152F
      Direct official label access enabled
      true
      Source IDH51-2CDD367396AC8676C15FC175
      Outbound server request required
      false
      Source IDH51-5011DAD5882773B11C481696
      Local summary status
      current_reviewed_summary
      Source IDH51-35FAC280FF081F3002CAF215
      Clinical review
      Locally normalized
      false
      Source IDH51-0393760F807CE4F767B334F5
      Reviewed
      2026-08-29
      Source IDH51-2482E689087545D88A6236E1
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-1A1BCE78094809D9A17F2532
      Clinical release verification
      Audit version
      3.4
      Source IDH51-BE99D0AB58E0E57951737783
      Audited on
      2026-08-30
      Source IDH51-96CE1E469AD09EDB8924CAD0
      Level
      amber
      Source IDH51-881397AB98954487E7F33156
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-C82003BAEDF035C885897B33
      Exact current label candidate
      false
      Source IDH51-86A7F9BBC53C1962586CC9E6
      Reference url count
      4
      Source IDH51-16CBE488E1124CE099C9BBA9
      Broken reference count
      0
      Source IDH51-35D4AF0137B934E69EAC63AA
      Point of use confirmation required
      true
      Source IDH51-B5BAB7EE965229DB891377C9
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-5C10CB152112352BFEF0ABB8
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      ambisome-liposomal-amphotericin-b
      Source IDH51-A3CD22FCFECA8E7F6800F180
      Name
      Ambisome (liposomal amphotericin B)
      Source IDH51-A5807FFEA0BDE0D6522D4A2A
      Therapeutic class
      Antifungal
      Source IDH51-7E525E9E16F2DCDEA56FBB6D
      Review version
      3.8
      Source IDH51-0640AC5C76ACA93C2C1374D3
      Review date
      2026-08-30
      Source IDH51-E6C2BA3DCCA1BC102777E146
      Release status
      reviewed_local_label_summary_exact_product_confirmation_required
      Source IDH51-E67007E5E3EBDE5BB9350D48
      Market status
      Status
      current_dailymed_label_page_located_exact_product_verification_required
      Source IDH51-47DD1A6D20174904A0811F9E
      Basis
      Current DailyMed label page located during the 2026-08-30 review; confirm the exact NDC and marketed product at the point of use.
      Source IDH51-11739106C7E8CD4F7DC81235
      Ten point assessment
      Exact formulation
      50 mg liposomal amphotericin B lyophilized vial.
      Source IDH51-94CBFD971625B8271340DC03
      Reconstitution concentration
      Reconstitute each 50 mg vial with 12 mL Sterile Water for Injection to produce 4 mg/mL. Do not reconstitute with saline or add a bacteriostatic agent. 4 mg/mL after labeled reconstitution.
      Source IDH51-5E7FA0660AEA3B39CB33A7AE
      Maximum or recommended final concentration
      Common labeled final concentrations are 1 to 2 mg/mL; lower concentrations may be required for infants and small children.
      Source IDH51-B94BB8167F2EAAE49E7A973E
      Appropriate standardized containers
      Select a D5W container that produces the labeled final concentration and accommodates the total dose volume.
      Source IDH51-1D1D8B078F288CBA83611E46
      Adult dosing range
      Adult dosing is indication- and patient-specific.
      Source IDH51-BB21F631ECCC261AD00E4EE2
      Pediatric dosing range
      Pediatric use is label supported for selected indications; concentration and fluid volume require weight-appropriate review.
      Source IDH51-9EF769C54ABAA7E0252019AF
      Neonatal dosing range
      Do not infer neonatal dosing from adult tables; use neonatal infectious-disease guidance and the current label.
      Source IDH51-03CAC1FB666AEB09CCD836FA
      Infusion time
      Usually infuse over approximately 120 minutes; the current label describes circumstances in which a shorter infusion may be used in a tolerant patient.
      Source IDH51-0D94CBCF0201E57362FB63E1
      Fluid restriction alternatives
      Do not exceed the labeled maximum concentration. Any concentrated preparation requires exact-product and institutional verification.
      Source IDH51-26DCEAB0578E0FCB55382C75
      Current manufacturer labeling
      Setid
      f7be6506-4d20-401e-a0ff-02ad7c33158a
      Source IDH51-61334DD0414D0A2DC872CBC2
      Title
      Amphotericin B liposome for injection (AmBisome)
      Source IDH51-0BF56C7B155421C1C7BBF594
      Routes
      1. INTRAVENOUS
        Source IDH51-4B27EFCA28CF0FABCE7B9345
      Match confidence
      reviewed_local_label_summary
      Source IDH51-AD6683856E0088967908D53A
      Field provenance
      Exact formulation
      Primary
      official_dailymed_local_label_summary
      Source IDH51-5E79CBEC020AA70588C860C9
      Reconstitution concentration
      Primary
      official_dailymed_local_label_summary
      Source IDH51-6DE4DE71074989B8399629F7
      Maximum or recommended final concentration
      Primary
      official_dailymed_local_label_summary
      Source IDH51-F62AE7E93EEC830F3573EDEE
      Appropriate standardized containers
      Primary
      official_dailymed_local_label_summary
      Source IDH51-C3D89E461E7CD368D595315C
      Adult dosing range
      Primary
      official_dailymed_local_label_summary
      Source IDH51-D438BFAEB32EB9977C488EE7
      Pediatric dosing range
      Primary
      official_dailymed_local_label_summary
      Source IDH51-69245B1EC763C462B3F8C650
      Neonatal dosing range
      Primary
      official_dailymed_local_label_summary
      Source IDH51-89F83C08F35582C4DB773B04
      Infusion time
      Primary
      official_dailymed_local_label_summary
      Source IDH51-D8BCB7BD6C9B0E2670305F7D
      Fluid restriction alternatives
      Primary
      official_dailymed_local_label_summary
      Source IDH51-889A1D2B6C989953AEC6356D
      Current manufacturer labeling
      Primary
      official_dailymed_local_label_summary
      Source IDH51-B6E905827CB646FF893439B3
      Population applicability
      Adult
      Applicability
      supported_or_source_present
      Source IDH51-4CD007C80B527DF38150FBB6
      Guide generation allowed
      false
      Source IDH51-1B6C3EC8AD6587F12F9613C6
      Pediatric
      Applicability
      supported_or_source_present
      Source IDH51-DF05899390D4470C1AEE0E1D
      Guide generation allowed
      false
      Source IDH51-69EA6D71FDD6B8D8DAD7B187
      Neonatal
      Applicability
      not_established_or_requires_separate_guidance
      Source IDH51-2126AD6D9B0EAAB27A3CF1FF
      Guide generation allowed
      false
      Source IDH51-888D79156779A0EAE3318F48
      Route presence
      Structured dilution
      false
      Source IDH51-57752EFE65C5C32F85C0EC9D
      Iv push
      false
      Source IDH51-76DD5FB03D3B8AE2043F0637
      Continuous infusion
      true
      Source IDH51-DCAEFFC8850F93D5956840AB
      Pediatric source
      true
      Source IDH51-0FE7BACD5B513728B598C258
      Neonatal source
      true
      Source IDH51-F4328EDFF0716019C8C7BFC1
      Legacy reference
      Status
      not_available
      Source IDH51-F6A73781B30BCD3D7FA99577
      Label resolution
      Status
      reviewed_current_official_label_page
      Source IDH51-C9CD9B5AFAAF4652F7EEC09D
      Existing setids
      1. f7be6506-4d20-401e-a0ff-02ad7c33158a
        Source IDH51-909A24EBB963642A43810A47
      Review date
      2026-08-30
      Source IDH51-FD09EAE335C33951704FC71B
      Source files
      1. catalog.json
        Source IDH51-45E0D46B304114F3E6B91F72
      2. dosing.json
        Source IDH51-75381AEC9872EA9C71376D2B
      3. legacy-map.json
        Source IDH51-790D5B4ECDA4CDE2458D9C88
      4. review-queue.json
        Source IDH51-7F7BAB7B56F03C7C5812B5E9
      Clinical release note
      Reviewed local summary is available. Confirm exact formulation, NDC, manufacturer, route, current marketed status, compatibility, and institutional policy before use.
      Source IDH51-7CEE32BCB136326063772CB1
      Has bundled label summary
      true
      Source IDH51-275C0D9A89E15CF7B2DF0CE6
      Bundled label summary id
      ambisome
      Source IDH51-06D513C7E24636D6EBCE5362
      Bundled label review date
      2026-08-30
      Source IDH51-983B63DDD2596F5552ADC73E
      Local label search
      ambisome Ambisome Liposomal amphotericin B Amphotericin B liposomal Amphotericin B liposome for injection (AmBisome) AmBisome 50 mg liposomal amphotericin B lyophilized vial. Reconstitute each 50 mg vial with 12 mL Sterile Water for Injection to produce 4 mg/mL. Do not reconstitute with saline or add a bacteriostatic agent. 4 mg/mL after labeled reconstitution. Further dilute only with 5% dextrose injection unless the exact current label states otherwise. Common labeled final concentrations are 1 to 2 mg/mL; lower concentrations may be required for infants and small children. Select a D5W container that produces the labeled final concentration and accommodates the total dose volume. Usually infuse over approximately 120 minutes; the current label describes circumstances in which a shorter infusion may be used in a tolerant patient. Do not exceed the labeled maximum concentration. Any concentrated preparation requires exact-product and institutional verification. Follow the current product label for reconstituted and diluted storage limits and protect from inappropriate temperatures or light as directed. Flush an existing line with D5W or use a separate line. If a filter is used, confirm the product-specific pore-size requirement. Adult dosing is indication- and patient-specific. Pediatric use is label supported for selected indications; concentration and fluid volume require weight-appropriate review. Do not infer neonatal dosing from adult tables; use neonatal infectious-disease guidance and the current label. No routine dose table substitutes for close renal, electrolyte, hepatic, and hematologic monitoring. AmBisome is not interchangeable on a mg-per-mg basis with other amphotericin B products. Use D5W, not saline, for final dilution. ambisome-liposomal-amphotericin-b Ambisome (liposomal amphotericin B) 2026-08-30 Reviewed local summary derived from official DailyMed labeling; exact marketed product must be checked. DailyMed official search
      Source IDH51-673A321F5BA1A2BE2C8A4822
      Aliases
      1. Amphotericin B liposome for injection (AmBisome)
        Source IDH51-2FFF382A3C3C0505A1A69E63
      2. 4 mg/mL after labeled reconstitution.
        Source IDH51-CE6C9C17137ECFFCBCF32221
      3. Further dilute only with 5% dextrose injection unless the exact current label states otherwise.
        Source IDH51-BFF77C4AE3B99CD7382B3A03
      4. Common labeled final concentrations are 1 to 2 mg/mL; lower concentrations may be required for infants and small children.
        Source IDH51-3D04962D8438CF35C2203D9A
      5. Usually infuse over approximately 120 minutes; the current label describes circumstances in which a shorter infusion may be used in a tolerant patient.
        Source IDH51-46C1AA0A513A32D1D060630D
      Local label summary
      Available
      true
      Source IDH51-F82613BA18FAC34A3A0CDE90
      Status level
      current
      Source IDH51-1447E4C441BC4CC6BD82D618
      Title
      Amphotericin B liposome for injection (AmBisome)
      Source IDH51-0F342AA734218A894EFD674C
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-EE22EE97830911ADD25A4EFDcatalog.json
      /records/11/id      		Historical; current review incomplete
      H51-ED0D8C3426D779DA2F3C2EECcatalog.json
      /records/11/legacy_title      		Historical; current review incomplete
      H51-D9117625DE231D1DC821900Fcatalog.json
      /records/11/generic_name      		Historical; current review incomplete
      H51-F68C74B4AFA44527B64C0DABcatalog.json
      /records/11/class      		Historical; current review incomplete
      H51-00DDE1BCC3EA3EB2B9253433catalog.json
      /records/11/subclass      		Historical; current review incomplete
      H51-57A6F7A8F856B02CF28260D8catalog.json
      /records/11/summary      		Historical; current review incomplete
      H51-8A5193B535CCDEC9199BC142catalog.json
      /records/11/warnings/0      		Historical; current review incomplete
      H51-16961C24CEBFE204BE3525A3catalog.json
      /records/11/stability_notes/0      		Historical; current review incomplete
      H51-2FC5004EC7ACC0E1BA831DACcatalog.json
      /records/11/populations/0      		Historical; current review incomplete
      H51-342A34C8EDB74F98AF7B26BFcatalog.json
      /records/11/evidence_tier      		Historical; current review incomplete
      H51-05AEA2A4E81644CF7AF5BFCAcatalog.json
      /records/11/high_alert      		Historical; current review incomplete
      H51-344BEEE94362FCBA35EB1676catalog.json
      /records/11/hazardous      		Historical; current review incomplete
      H51-186F32C63B482092DE78A46Ecatalog.json
      /records/11/status      		Historical; current review incomplete
      H51-A4565211F201D3B3D8EE7461catalog.json
      /records/11/reviewed      		Historical; current review incomplete
      H51-8982F134A103365C13696D3Bcatalog.json
      /records/11/version_added      		Historical; current review incomplete
      H51-282001229BA41D2A382DC95Bcatalog.json
      /records/11/sources/0      		Historical; current review incomplete
      H51-7F03E718CE886656E56E2377catalog.json
      /records/11/sources/0/label      		Historical; current review incomplete
      H51-1C075F904868FFD3CA1E9105catalog.json
      /records/11/sources/0/url      		Historical; current review incomplete
      H51-5082A15E628B1394953F6767catalog.json
      /records/11/sources/0/kind      		Historical; current review incomplete
      H51-F593033C0C6A5FFDE75A7D32catalog.json
      /records/11/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-7446623E0737D6AD09A9D038catalog.json
      /records/11/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-C2F3F2F89656779C491ABF9Bcatalog.json
      /records/11/clinical_release_verification/level      		Historical; current review incomplete
      H51-8C8B1311851308C31C2ACFE6catalog.json
      /records/11/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-C7F045C2620858E5131584B5catalog.json
      /records/11/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-5526DDA07BD1E87556222707catalog.json
      /records/11/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-6959AD00334E5329153C70C3catalog.json
      /records/11/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-07DF50BEBB366650C36D4AE3catalog.json
      /records/11/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-45EB51BCC8A6ECCECBB8E8E6catalog.json
      /records/11/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-2C4D35A7230C555C6D85A4C0catalog.json
      /records/11/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-CC28B6C7C300276601A768D5catalog.json
      /records/11/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-243B131340D4ED8B2497B37Ccatalog.json
      /records/11/clinical_release_verification/note      		Historical; current review incomplete
      H51-4233551B74963F518B64EC71catalog.json
      /records/11/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-08227AB5EF798D8F83824BD4catalog.json
      /records/11/version_updated      		Historical; current review incomplete
      H51-BE6AC216367D4CB4C5482362dailymed-label-snapshots-v5.1.json
      /records/1/id      		Historical; current review incomplete
      H51-FAA8128B89D4358A4953EBD4dailymed-label-snapshots-v5.1.json
      /records/1/catalog_name      		Historical; current review incomplete
      H51-2CA78D8672B3E87CAEFD34FEdailymed-label-snapshots-v5.1.json
      /records/1/selection_status      		Historical; current review incomplete
      H51-A82CE309F04AF042DCECC4C1dailymed-label-snapshots-v5.1.json
      /records/1/confidence      		Historical; current review incomplete
      H51-BE01EB6107A756C9A78CBD76dailymed-label-snapshots-v5.1.json
      /records/1/match_path      		Historical; current review incomplete
      H51-FCEC1E6FC54F9B7AB90FF7A9dailymed-label-snapshots-v5.1.json
      /records/1/brand_name      		Historical; current review incomplete
      H51-1512779A0B19D095C95E3414dailymed-label-snapshots-v5.1.json
      /records/1/label_title      		Historical; current review incomplete
      H51-61F45EC8D8B4620E12997B32dailymed-label-snapshots-v5.1.json
      /records/1/labeler      		Historical; current review incomplete
      H51-7944DAD3233378DB29E8FE50dailymed-label-snapshots-v5.1.json
      /records/1/setid      		Historical; current review incomplete
      H51-9505F3926FABB3F8A414DE0Bdailymed-label-snapshots-v5.1.json
      /records/1/official_label_url      		Historical; current review incomplete
      H51-F0ED16EDCBA025D6E5942C51dailymed-label-snapshots-v5.1.json
      /records/1/reviewed_on      		Historical; current review incomplete
      H51-69197839DCD5D70B09B1C7F0dailymed-label-snapshots-v5.1.json
      /records/1/route      		Historical; current review incomplete
      H51-BC26C1380018636784DA5615dailymed-label-snapshots-v5.1.json
      /records/1/dosage_form      		Historical; current review incomplete
      H51-B632DB20DF029BCBFD623E93dailymed-label-snapshots-v5.1.json
      /records/1/dosage_administration_summary/0      		Historical; current review incomplete
      H51-ECDEBAC7B3CBEC4E0EA0258Cdailymed-label-snapshots-v5.1.json
      /records/1/dosage_administration_summary/1      		Historical; current review incomplete
      H51-3B1043FA26B699014DF619CEdailymed-label-snapshots-v5.1.json
      /records/1/dosage_administration_summary/2      		Historical; current review incomplete
      H51-744CA13C4D139FC0436F95F0dailymed-label-snapshots-v5.1.json
      /records/1/dosage_administration_summary/3      		Historical; current review incomplete
      H51-A8B8340ADBECE5E97412DC38dailymed-label-snapshots-v5.1.json
      /records/1/dosage_administration_summary/4      		Historical; current review incomplete
      H51-CD508AA8388AE1E84547EEF8dailymed-label-snapshots-v5.1.json
      /records/1/dosage_administration_summary/5      		Historical; current review incomplete
      H51-570F48FA88EEF053C74768FFdailymed-label-snapshots-v5.1.json
      /records/1/dosage_forms_strengths/0      		Historical; current review incomplete
      H51-08C2A614ED7C192C9B61DB2Adailymed-label-snapshots-v5.1.json
      /records/1/dosage_forms_strengths/1      		Historical; current review incomplete
      H51-D590013D5FEAD957B3F7CD57dailymed-label-snapshots-v5.1.json
      /records/1/mechanism_summary      		Historical; current review incomplete
      H51-A6671D9EB461E01009592A09dailymed-label-snapshots-v5.1.json
      /records/1/mechanism_source      		Historical; current review incomplete
      H51-7B1D97856BDFC423830236FFdailymed-label-snapshots-v5.1.json
      /records/1/scope_note      		Historical; current review incomplete
      H51-B7AB4BE7AB0D106267029ACAdailymed-label-snapshots-v5.1.json
      /records/1/source_sections/0      		Historical; current review incomplete
      H51-7F726265DF87E066D27FD7F0dailymed-label-snapshots-v5.1.json
      /records/1/source_sections/1      		Historical; current review incomplete
      H51-4263441EF035B58ACE17731Bdailymed-label-snapshots-v5.1.json
      /records/1/source_sections/2      		Historical; current review incomplete
      H51-44F23C88A2F2D61EDC0843B2dailymed-label-snapshots-v5.1.json
      /records/1/retrieval_method      		Historical; current review incomplete
      H51-25608FE3F005602E957189E0dailymed-label-snapshots-v5.1.json
      /records/1/label_status      		Historical; current review incomplete
      H51-9C7473BD575C67484796B130dailymed-label-snapshots-v5.1.json
      /records/1/disclaimer      		Historical; current review incomplete
      H51-CCD004BFDF132299EBA0DDD4dosing.json
      /records/11/id      		Historical; current review incomplete
      H51-53CD31D35B9564F71F1AA19Edosing.json
      /records/11/generic_name      		Historical; current review incomplete
      H51-8276D0CEA146FE7DD24D31E0dosing.json
      /records/11/coverage_status      		Historical; current review incomplete
      H51-5C61E27645014EF498999B54dosing.json
      /records/11/package_insert/query_name      		Historical; current review incomplete
      H51-F6B2644D49F1A034C72D99FFdosing.json
      /records/11/package_insert/preferred_setid      		Historical; current review incomplete
      H51-6DC6F411CD4F107C1A46EDDAdosing.json
      /records/11/package_insert/product_and_route_must_match      		Historical; current review incomplete
      H51-12DB8433F46C02D9B89F0620dosing.json
      /records/11/package_insert/live_current_label_enabled      		Historical; current review incomplete
      H51-87815D73001543C0F422152Fdosing.json
      /records/11/package_insert/source_priority      		Historical; current review incomplete
      H51-2CDD367396AC8676C15FC175dosing.json
      /records/11/package_insert/direct_official_label_access_enabled      		Historical; current review incomplete
      H51-5011DAD5882773B11C481696dosing.json
      /records/11/package_insert/outbound_server_request_required      		Historical; current review incomplete
      H51-35FAC280FF081F3002CAF215dosing.json
      /records/11/package_insert/local_summary_status      		Historical; current review incomplete
      H51-20AC4E52BF1A786F7E748AEFdosing.json
      /records/11/renal/classification      		Historical; current review incomplete
      H51-A2AFC8E015718F516F2EF377dosing.json
      /records/11/renal/summary      		Historical; current review incomplete
      H51-31AFA6F8BB2276B675806B0Edosing.json
      /records/11/renal/method_note      		Historical; current review incomplete
      H51-A6E12075903CDD5891491177dosing.json
      /records/11/professional_sources/0      		Historical; current review incomplete
      H51-E3F85CC4D816910EBF367826dosing.json
      /records/11/professional_sources/0/label      		Historical; current review incomplete
      H51-45D6CFF74CC06B936D2E5EE0dosing.json
      /records/11/professional_sources/0/url      		Historical; current review incomplete
      H51-D18B84513D42952B9E23F276dosing.json
      /records/11/professional_sources/0/kind      		Historical; current review incomplete
      H51-8D4BAD3B704EB3A55B7DCEE6dosing.json
      /records/11/professional_sources/1      		Historical; current review incomplete
      H51-DB5EEEC16FFE6D3E4B7A1B72dosing.json
      /records/11/professional_sources/1/label      		Historical; current review incomplete
      H51-19ECB5009D4D1B95C742F7F0dosing.json
      /records/11/professional_sources/1/url      		Historical; current review incomplete
      H51-737244BE32AC3EF6F6272ABFdosing.json
      /records/11/professional_sources/1/kind      		Historical; current review incomplete
      H51-966DC71EC4026E35524E09E2dosing.json
      /records/11/professional_sources/2      		Historical; current review incomplete
      H51-AB7B696C98D1EB497C275982dosing.json
      /records/11/professional_sources/2/label      		Historical; current review incomplete
      H51-8C3B2C64261D047B63B41882dosing.json
      /records/11/professional_sources/2/url      		Historical; current review incomplete
      H51-5D9D3C8B1B8821FB8CF2C5BCdosing.json
      /records/11/professional_sources/2/kind      		Historical; current review incomplete
      H51-F671D436A602C2FAF86417C2dosing.json
      /records/11/professional_sources/3      		Historical; current review incomplete
      H51-1BDD38A4EABC3E2DF6714631dosing.json
      /records/11/professional_sources/3/label      		Historical; current review incomplete
      H51-B7E39F9312128BF1D5834F44dosing.json
      /records/11/professional_sources/3/url      		Historical; current review incomplete
      H51-E386E5A958B2DF4108F8297Bdosing.json
      /records/11/professional_sources/3/kind      		Historical; current review incomplete
      H51-0393760F807CE4F767B334F5dosing.json
      /records/11/clinical_review/locally_normalized      		Historical; current review incomplete
      H51-2482E689087545D88A6236E1dosing.json
      /records/11/clinical_review/reviewed      		Historical; current review incomplete
      H51-1A1BCE78094809D9A17F2532dosing.json
      /records/11/clinical_review/status      		Historical; current review incomplete
      H51-BE99D0AB58E0E57951737783dosing.json
      /records/11/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-96CE1E469AD09EDB8924CAD0dosing.json
      /records/11/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-881397AB98954487E7F33156dosing.json
      /records/11/clinical_release_verification/level      		Historical; current review incomplete
      H51-C82003BAEDF035C885897B33dosing.json
      /records/11/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-86A7F9BBC53C1962586CC9E6dosing.json
      /records/11/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-5ECA3BAF55C659E1C75F86B6dosing.json
      /records/11/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-B137575F9C96DCA127CC37D8dosing.json
      /records/11/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-B94DA7DEA8052D8DB387D2A8dosing.json
      /records/11/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-16CBE488E1124CE099C9BBA9dosing.json
      /records/11/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-35D4AF0137B934E69EAC63AAdosing.json
      /records/11/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-B5BAB7EE965229DB891377C9dosing.json
      /records/11/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-5C10CB152112352BFEF0ABB8dosing.json
      /records/11/clinical_release_verification/note      		Historical; current review incomplete
      H51-94F0A66A0D2F10F2506134AEdosing.json
      /records/11/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-83300AA57A64233B45BD70A5first-look-v5.1.json
      /records/11/id      		Historical; current review incomplete
      H51-34ECBED910BAE5AC00C7E80Dfirst-look-v5.1.json
      /records/11/generic_name      		Historical; current review incomplete
      H51-C039C7A277A854CCBCC2EFC1first-look-v5.1.json
      /records/11/class      		Historical; current review incomplete
      H51-4DE2AB6F698786B4718899CEfirst-look-v5.1.json
      /records/11/subclass      		Historical; current review incomplete
      H51-F7F1DFE769500BDB339262E4first-look-v5.1.json
      /records/11/primary_uses/0      		Historical; current review incomplete
      H51-42F7147AF4A697C674EA0A24first-look-v5.1.json
      /records/11/mechanism      		Historical; current review incomplete
      H51-3A7E30D1E1FA91AC41709FCBfirst-look-v5.1.json
      /records/11/mechanism_level      		Historical; current review incomplete
      H51-65C0079D43A62B31B9945AE7first-look-v5.1.json
      /records/11/basic_dosing_orientation      		Historical; current review incomplete
      H51-44963218DC43B59592DEA111first-look-v5.1.json
      /records/11/administration_orientation      		Historical; current review incomplete
      H51-D7A5A34B5CC396DE54768D66first-look-v5.1.json
      /records/11/renal_and_population_orientation      		Historical; current review incomplete
      H51-9321FC0EEF8D8DC9844A540Dfirst-look-v5.1.json
      /records/11/key_safety_orientation/0      		Historical; current review incomplete
      H51-5F4C4E5D1020BFD566A0D130first-look-v5.1.json
      /records/11/key_safety_orientation/1      		Historical; current review incomplete
      H51-8E09C87731A96326185F8A49first-look-v5.1.json
      /records/11/coverage_path      		Historical; current review incomplete
      H51-4C4123A66678B73B5BDB52CFfirst-look-v5.1.json
      /records/11/coverage_path_label      		Historical; current review incomplete
      H51-E8BAFC9261B276D516450370first-look-v5.1.json
      /records/11/official_label_url      		Historical; current review incomplete
      H51-BD36CE9EBED6A449FF1F8AB3first-look-v5.1.json
      /records/11/legacy_title      		Historical; current review incomplete
      H51-E3B0A85D97BABC1F8FC3F961first-look-v5.1.json
      /records/11/review_note      		Historical; current review incomplete
      H51-463F8355A3EF11CDED6BA541first-look-v5.1.json
      /records/11/search_text      		Historical; current review incomplete
      H51-A37FE0583EDF0C80B6AD87D9first-look-v5.1.json
      /records/11/official_search_url      		Historical; current review incomplete
      H51-4C67208887D2E7B3E28A84A7first-look-v5.1.json
      /records/11/official_access_mode      		Historical; current review incomplete
      H51-AB2FEE91AD480186485B48B8first-look-v5.1.json
      /records/11/official_access_url      		Historical; current review incomplete
      H51-35188B6488260B3863130A51first-look-v5.1.json
      /records/11/official_search_query      		Historical; current review incomplete
      H51-57D78EFEFF33A0E51E322A19first-look-v5.1.json
      /records/11/official_access_reason      		Historical; current review incomplete
      H51-6D5EB9950BEF5CA698060862first-look-v5.1.json
      /records/11/label_snapshot_available      		Historical; current review incomplete
      H51-CA1D3751BAEB6F884863D295first-look-v5.1.json
      /records/11/label_snapshot_setid      		Historical; current review incomplete
      H51-4F93DE66CB2CA91E91E3D9CElocal-label-summaries-v3.8.json
      /summaries/1/id      		Historical; current review incomplete
      H51-C12E4FA13C50E69569BC217Dlocal-label-summaries-v3.8.json
      /summaries/1/match_names/0      		Historical; current review incomplete
      H51-47DED0C5B8771182C0CCFEFElocal-label-summaries-v3.8.json
      /summaries/1/match_names/1      		Historical; current review incomplete
      H51-1CC04D679E0CA53F7B08C696local-label-summaries-v3.8.json
      /summaries/1/match_names/2      		Historical; current review incomplete
      H51-3A208A49171ADBF4D76E4239local-label-summaries-v3.8.json
      /summaries/1/label_title      		Historical; current review incomplete
      H51-668005E89BFDFFA98AFD2B24local-label-summaries-v3.8.json
      /summaries/1/brand_names/0      		Historical; current review incomplete
      H51-74A011348366CF8A15371602local-label-summaries-v3.8.json
      /summaries/1/formulation      		Historical; current review incomplete
      H51-1C5848AC70FCC1224EE84133local-label-summaries-v3.8.json
      /summaries/1/reconstitution      		Historical; current review incomplete
      H51-E868FB133B554AFFCC0BA08Alocal-label-summaries-v3.8.json
      /summaries/1/stock_concentration      		Historical; current review incomplete
      H51-668A45BA8A5088E22F669451local-label-summaries-v3.8.json
      /summaries/1/diluents      		Historical; current review incomplete
      H51-4159E4F0455792518A142F09local-label-summaries-v3.8.json
      /summaries/1/final_concentration      		Historical; current review incomplete
      H51-DF0E9D91E128D06349DA903Alocal-label-summaries-v3.8.json
      /summaries/1/containers      		Historical; current review incomplete
      H51-63CAD45445BB982C226A9B6Blocal-label-summaries-v3.8.json
      /summaries/1/infusion_time      		Historical; current review incomplete
      H51-DDD89C0663E4F121F78DE837local-label-summaries-v3.8.json
      /summaries/1/fluid_restriction      		Historical; current review incomplete
      H51-5D51D4FD7EB070556F36CD80local-label-summaries-v3.8.json
      /summaries/1/stability      		Historical; current review incomplete
      H51-E4C564C7B598BA2ED93C0947local-label-summaries-v3.8.json
      /summaries/1/line_filter      		Historical; current review incomplete
      H51-C404AF8DCAEBCE4EAD918BC1local-label-summaries-v3.8.json
      /summaries/1/adult_applicability      		Historical; current review incomplete
      H51-6FC49F23901A9D01435C947Elocal-label-summaries-v3.8.json
      /summaries/1/pediatric_applicability      		Historical; current review incomplete
      H51-1747A2F8CCC20316539FC7BAlocal-label-summaries-v3.8.json
      /summaries/1/neonatal_applicability      		Historical; current review incomplete
      H51-923D9E64D7B3E5404D8FA614local-label-summaries-v3.8.json
      /summaries/1/renal_dialysis      		Historical; current review incomplete
      H51-350D54DCDC9CD04FBBC5C923local-label-summaries-v3.8.json
      /summaries/1/key_warnings      		Historical; current review incomplete
      H51-9EC1CA100738F92CCBB930F4local-label-summaries-v3.8.json
      /summaries/1/catalog_id      		Historical; current review incomplete
      H51-A3AE0D7C71A88F72A16B5D0Dlocal-label-summaries-v3.8.json
      /summaries/1/catalog_name      		Historical; current review incomplete
      H51-E5458F60390C7966CE0E78B6local-label-summaries-v3.8.json
      /summaries/1/review_date      		Historical; current review incomplete
      H51-DD06B139F8E60CF971ADD79Elocal-label-summaries-v3.8.json
      /summaries/1/source_type      		Historical; current review incomplete
      H51-B1DE79BC33E0299B8A8BF096local-label-summaries-v3.8.json
      /summaries/1/official_link_type      		Historical; current review incomplete
      H51-8085EDC5C33B229A8106B392local-label-summaries-v3.8.json
      /summaries/1/official_label_url      		Historical; current review incomplete
      H51-84A7C2D509D65594962C2564local-label-summaries-v3.8.json
      /summaries/1/official_search_url      		Historical; current review incomplete
      H51-2C996FC70F7AFA981782DD1Dlocal-label-summaries-v3.8.json
      /summaries/1/search_text      		Historical; current review incomplete
      H51-58346D01D0E3853E51DD66F8local-label-summaries-v3.8.json
      /summaries/1/label_status      		Historical; current review incomplete
      H51-04F0128E8097FBDBAAEDA43Blocal-label-summaries-v3.8.json
      /summaries/1/label_status_level      		Historical; current review incomplete
      H51-A3CD22FCFECA8E7F6800F180preparation-assessments-v3.8.json
      /11/id      		Historical; current review incomplete
      H51-A5807FFEA0BDE0D6522D4A2Apreparation-assessments-v3.8.json
      /11/name      		Historical; current review incomplete
      H51-1BDF9883ED8B4DA103906A9Apreparation-assessments-v3.8.json
      /11/brands      		Historical; current review incomplete
      H51-7E525E9E16F2DCDEA56FBB6Dpreparation-assessments-v3.8.json
      /11/therapeutic_class      		Historical; current review incomplete
      H51-0640AC5C76ACA93C2C1374D3preparation-assessments-v3.8.json
      /11/review_version      		Historical; current review incomplete
      H51-E6C2BA3DCCA1BC102777E146preparation-assessments-v3.8.json
      /11/review_date      		Historical; current review incomplete
      H51-E67007E5E3EBDE5BB9350D48preparation-assessments-v3.8.json
      /11/release_status      		Historical; current review incomplete
      H51-47DD1A6D20174904A0811F9Epreparation-assessments-v3.8.json
      /11/market_status/status      		Historical; current review incomplete
      H51-11739106C7E8CD4F7DC81235preparation-assessments-v3.8.json
      /11/market_status/basis      		Historical; current review incomplete
      H51-94CBFD971625B8271340DC03preparation-assessments-v3.8.json
      /11/ten_point_assessment/exact_formulation      		Historical; current review incomplete
      H51-5E7FA0660AEA3B39CB33A7AEpreparation-assessments-v3.8.json
      /11/ten_point_assessment/reconstitution_concentration      		Historical; current review incomplete
      H51-B94BB8167F2EAAE49E7A973Epreparation-assessments-v3.8.json
      /11/ten_point_assessment/maximum_or_recommended_final_concentration      		Historical; current review incomplete
      H51-1D1D8B078F288CBA83611E46preparation-assessments-v3.8.json
      /11/ten_point_assessment/appropriate_standardized_containers      		Historical; current review incomplete
      H51-BB21F631ECCC261AD00E4EE2preparation-assessments-v3.8.json
      /11/ten_point_assessment/adult_dosing_range      		Historical; current review incomplete
      H51-9EF769C54ABAA7E0252019AFpreparation-assessments-v3.8.json
      /11/ten_point_assessment/pediatric_dosing_range      		Historical; current review incomplete
      H51-03CAC1FB666AEB09CCD836FApreparation-assessments-v3.8.json
      /11/ten_point_assessment/neonatal_dosing_range      		Historical; current review incomplete
      H51-0D94CBCF0201E57362FB63E1preparation-assessments-v3.8.json
      /11/ten_point_assessment/infusion_time      		Historical; current review incomplete
      H51-26DCEAB0578E0FCB55382C75preparation-assessments-v3.8.json
      /11/ten_point_assessment/fluid_restriction_alternatives      		Historical; current review incomplete
      H51-61334DD0414D0A2DC872CBC2preparation-assessments-v3.8.json
      /11/ten_point_assessment/current_manufacturer_labeling/setid      		Historical; current review incomplete
      H51-0BF56C7B155421C1C7BBF594preparation-assessments-v3.8.json
      /11/ten_point_assessment/current_manufacturer_labeling/title      		Historical; current review incomplete
      H51-B32E8D8E102ADB743EF43199preparation-assessments-v3.8.json
      /11/ten_point_assessment/current_manufacturer_labeling/published_date      		Historical; current review incomplete
      H51-BC08B0AF1E80E143B55C55AEpreparation-assessments-v3.8.json
      /11/ten_point_assessment/current_manufacturer_labeling/manufacturer      		Historical; current review incomplete
      H51-4B27EFCA28CF0FABCE7B9345preparation-assessments-v3.8.json
      /11/ten_point_assessment/current_manufacturer_labeling/routes/0      		Historical; current review incomplete
      H51-AD6683856E0088967908D53Apreparation-assessments-v3.8.json
      /11/ten_point_assessment/current_manufacturer_labeling/match_confidence      		Historical; current review incomplete
      H51-AFDCA06F648BCE26974ABE30preparation-assessments-v3.8.json
      /11/ten_point_assessment/current_manufacturer_labeling/url      		Historical; current review incomplete
      H51-5E79CBEC020AA70588C860C9preparation-assessments-v3.8.json
      /11/field_provenance/exact_formulation/primary      		Historical; current review incomplete
      H51-6DE4DE71074989B8399629F7preparation-assessments-v3.8.json
      /11/field_provenance/reconstitution_concentration/primary      		Historical; current review incomplete
      H51-F62AE7E93EEC830F3573EDEEpreparation-assessments-v3.8.json
      /11/field_provenance/maximum_or_recommended_final_concentration/primary      		Historical; current review incomplete
      H51-C3D89E461E7CD368D595315Cpreparation-assessments-v3.8.json
      /11/field_provenance/appropriate_standardized_containers/primary      		Historical; current review incomplete
      H51-D438BFAEB32EB9977C488EE7preparation-assessments-v3.8.json
      /11/field_provenance/adult_dosing_range/primary      		Historical; current review incomplete
      H51-69245B1EC763C462B3F8C650preparation-assessments-v3.8.json
      /11/field_provenance/pediatric_dosing_range/primary      		Historical; current review incomplete
      H51-89F83C08F35582C4DB773B04preparation-assessments-v3.8.json
      /11/field_provenance/neonatal_dosing_range/primary      		Historical; current review incomplete
      H51-D8BCB7BD6C9B0E2670305F7Dpreparation-assessments-v3.8.json
      /11/field_provenance/infusion_time/primary      		Historical; current review incomplete
      H51-889A1D2B6C989953AEC6356Dpreparation-assessments-v3.8.json
      /11/field_provenance/fluid_restriction_alternatives/primary      		Historical; current review incomplete
      H51-B6E905827CB646FF893439B3preparation-assessments-v3.8.json
      /11/field_provenance/current_manufacturer_labeling/primary      		Historical; current review incomplete
      H51-4CD007C80B527DF38150FBB6preparation-assessments-v3.8.json
      /11/population_applicability/adult/applicability      		Historical; current review incomplete
      H51-1B6C3EC8AD6587F12F9613C6preparation-assessments-v3.8.json
      /11/population_applicability/adult/guide_generation_allowed      		Historical; current review incomplete
      H51-DF05899390D4470C1AEE0E1Dpreparation-assessments-v3.8.json
      /11/population_applicability/pediatric/applicability      		Historical; current review incomplete
      H51-69EA6D71FDD6B8D8DAD7B187preparation-assessments-v3.8.json
      /11/population_applicability/pediatric/guide_generation_allowed      		Historical; current review incomplete
      H51-2126AD6D9B0EAAB27A3CF1FFpreparation-assessments-v3.8.json
      /11/population_applicability/neonatal/applicability      		Historical; current review incomplete
      H51-888D79156779A0EAE3318F48preparation-assessments-v3.8.json
      /11/population_applicability/neonatal/guide_generation_allowed      		Historical; current review incomplete
      H51-57752EFE65C5C32F85C0EC9Dpreparation-assessments-v3.8.json
      /11/route_presence/structured_dilution      		Historical; current review incomplete
      H51-76DD5FB03D3B8AE2043F0637preparation-assessments-v3.8.json
      /11/route_presence/iv_push      		Historical; current review incomplete
      H51-DCAEFFC8850F93D5956840ABpreparation-assessments-v3.8.json
      /11/route_presence/continuous_infusion      		Historical; current review incomplete
      H51-0FE7BACD5B513728B598C258preparation-assessments-v3.8.json
      /11/route_presence/pediatric_source      		Historical; current review incomplete
      H51-F4328EDFF0716019C8C7BFC1preparation-assessments-v3.8.json
      /11/route_presence/neonatal_source      		Historical; current review incomplete
      H51-F6A73781B30BCD3D7FA99577preparation-assessments-v3.8.json
      /11/legacy_reference/status      		Historical; current review incomplete
      H51-C9CD9B5AFAAF4652F7EEC09Dpreparation-assessments-v3.8.json
      /11/label_resolution/status      		Historical; current review incomplete
      H51-909A24EBB963642A43810A47preparation-assessments-v3.8.json
      /11/label_resolution/existing_setids/0      		Historical; current review incomplete
      H51-C2560C13D4AF5209FAF98612preparation-assessments-v3.8.json
      /11/label_resolution/official_url      		Historical; current review incomplete
      H51-FD09EAE335C33951704FC71Bpreparation-assessments-v3.8.json
      /11/label_resolution/review_date      		Historical; current review incomplete
      H51-45E0D46B304114F3E6B91F72preparation-assessments-v3.8.json
      /11/source_files/0      		Historical; current review incomplete
      H51-75381AEC9872EA9C71376D2Bpreparation-assessments-v3.8.json
      /11/source_files/1      		Historical; current review incomplete
      H51-790D5B4ECDA4CDE2458D9C88preparation-assessments-v3.8.json
      /11/source_files/2      		Historical; current review incomplete
      H51-7F7BAB7B56F03C7C5812B5E9preparation-assessments-v3.8.json
      /11/source_files/3      		Historical; current review incomplete
      H51-7CEE32BCB136326063772CB1preparation-assessments-v3.8.json
      /11/clinical_release_note      		Historical; current review incomplete
      H51-275C0D9A89E15CF7B2DF0CE6preparation-assessments-v3.8.json
      /11/has_bundled_label_summary      		Historical; current review incomplete
      H51-06D513C7E24636D6EBCE5362preparation-assessments-v3.8.json
      /11/bundled_label_summary_id      		Historical; current review incomplete
      H51-983B63DDD2596F5552ADC73Epreparation-assessments-v3.8.json
      /11/bundled_label_review_date      		Historical; current review incomplete
      H51-673A321F5BA1A2BE2C8A4822preparation-assessments-v3.8.json
      /11/local_label_search      		Historical; current review incomplete
      H51-2FFF382A3C3C0505A1A69E63preparation-assessments-v3.8.json
      /11/aliases/0      		Historical; current review incomplete
      H51-CE6C9C17137ECFFCBCF32221preparation-assessments-v3.8.json
      /11/aliases/1      		Historical; current review incomplete
      H51-BFF77C4AE3B99CD7382B3A03preparation-assessments-v3.8.json
      /11/aliases/2      		Historical; current review incomplete
      H51-3D04962D8438CF35C2203D9Apreparation-assessments-v3.8.json
      /11/aliases/3      		Historical; current review incomplete
      H51-46C1AA0A513A32D1D060630Dpreparation-assessments-v3.8.json
      /11/aliases/4      		Historical; current review incomplete
      H51-F82613BA18FAC34A3A0CDE90preparation-assessments-v3.8.json
      /11/local_label_summary/available      		Historical; current review incomplete
      H51-1447E4C441BC4CC6BD82D618preparation-assessments-v3.8.json
      /11/local_label_summary/status_level      		Historical; current review incomplete
      H51-0F342AA734218A894EFD674Cpreparation-assessments-v3.8.json
      /11/local_label_summary/title      		Historical; current review incomplete
      H51-9D722487505D72A8CF2A89C6preparation-assessments-v3.8.json
      /11/local_label_summary/official_url      		Historical; current review incomplete

      Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)

      All medicationsReturn to medication headingApplication top